Skip to Content
Uncategorized

Focus on Pharma

The Center for Biomedical Innovation is launched.
October 1, 2005

The institute’s latest multidisciplinary center–the MIT Center for Biomedical Innovation, which launched in July–is aiming to develop safer and more-efficient ways to commercialize pharmaceutical advances.

The center will include Institute researchers in science, engineering, and management, as well as scientists at Harvard Medical School. It will also draw on experts from government and industry to participate in research programs in policy, financial and risk assessment, and management. The center will be funded by government agencies, philanthropic organizations, and industry consortia.

In her keynote address at the annual meeting of the Massachusetts Biotechnology Council in May, MIT president Susan Hockfield said that the center will be a “safe harbor” where leaders in business, government, and academia can work on issues including drug safety; management of economic, financial, and regulatory risk; and manufacturing and delivery systems.

“The current system just isn’t working well anymore,” Hockfield said. “The productivity of large pharmaceutical innovation is declining. We can’t predict properly the side effects of new compounds, and we don’t have good ways to monitor and assess them once they are in the market.”

The center will not have its own laboratories; instead, it will collaborate with existing academic and commercial laboratories and hospitals. But it will focus heavily on real-world problems, and will combine technical and management solutions. The end result, the researchers hope, will be better and less expensive health care. – By Lisa Scanlon

paragraph one

Rest of the article

Deep Dive

Uncategorized

Embracing CX in the metaverse

More than just meeting customers where they are, the metaverse offers opportunities to transform customer experience.

Identity protection is key to metaverse innovation

As immersive experiences in the metaverse become more sophisticated, so does the threat landscape.

The modern enterprise imaging and data value chain

For both patients and providers, intelligent, interoperable, and open workflow solutions will make all the difference.

Scientists have created synthetic mouse embryos with developed brains

The stem-cell-derived embryos could shed new light on the earliest stages of human pregnancy.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.